Description of clinical complications occurring >2 years post-HCT
| . | ARTEMIS, n = 47 . | % of patients . | RAG, n = 45 . | % of patients . |
|---|---|---|---|---|
| Overall | 33 | 70 | 11 | 24 |
| cGVHD or autoimmunity: events (patients)* | 16 (14) | 30 | 10 (8) | 18 |
| Persistent cGVHD | 1 | 6 | ||
| AIHA/ITP | 4 | 3 | ||
| Myositis | 1 | 1 | ||
| Vitiligo | 4 | 0 | ||
| Severe asthma | 3 | 0 | ||
| Thyroiditis | 1 | 0 | ||
| Ill-defined autoinflammation | 1 | 0 | ||
| Disseminated granulomatous disease | 1 | 0 | ||
| Severe or recurrent infection: events (patients)* | 18 (16) | 34 | 6 (6) | 13 |
| Opportunistic infection | 4 | 1 | ||
| Chronic lung disease and/or chronic sinusitis | 13 | 4 | ||
| Severe bacterial sepsis | 1 | 1 | ||
| Miscellaneous:† events (patients)* | 13 (7) | 15 | 0 (0) | 0 |
| Growth hormone deficiency | 4 | 0 | ||
| Central hypothyroidism | 3 | 0 | ||
| IDDM | 2 | 0 | ||
| Renal tubulopathy | 2 | 0 | ||
| Exocrine pancreas insufficiency | 1 | 0 | ||
| Pulmonary fibrosis | 1 | 0 | ||
| Growth less than the third percentile‡ | 23 | 49 | 4 | 9 |
| Nutritional support‡ | 10 | 21 | 2 | 4 |
| Dental abnormalities‡ | 10 | 21 | 0 | 0 |
| Sequelae of pre-HCT morbidity‡ | 4 | 8.5 | 2 | 4.5 |
| Late deaths >2 y post-HCT‡ | 5 | 10.5 | 2 | 4.5 |
| . | ARTEMIS, n = 47 . | % of patients . | RAG, n = 45 . | % of patients . |
|---|---|---|---|---|
| Overall | 33 | 70 | 11 | 24 |
| cGVHD or autoimmunity: events (patients)* | 16 (14) | 30 | 10 (8) | 18 |
| Persistent cGVHD | 1 | 6 | ||
| AIHA/ITP | 4 | 3 | ||
| Myositis | 1 | 1 | ||
| Vitiligo | 4 | 0 | ||
| Severe asthma | 3 | 0 | ||
| Thyroiditis | 1 | 0 | ||
| Ill-defined autoinflammation | 1 | 0 | ||
| Disseminated granulomatous disease | 1 | 0 | ||
| Severe or recurrent infection: events (patients)* | 18 (16) | 34 | 6 (6) | 13 |
| Opportunistic infection | 4 | 1 | ||
| Chronic lung disease and/or chronic sinusitis | 13 | 4 | ||
| Severe bacterial sepsis | 1 | 1 | ||
| Miscellaneous:† events (patients)* | 13 (7) | 15 | 0 (0) | 0 |
| Growth hormone deficiency | 4 | 0 | ||
| Central hypothyroidism | 3 | 0 | ||
| IDDM | 2 | 0 | ||
| Renal tubulopathy | 2 | 0 | ||
| Exocrine pancreas insufficiency | 1 | 0 | ||
| Pulmonary fibrosis | 1 | 0 | ||
| Growth less than the third percentile‡ | 23 | 49 | 4 | 9 |
| Nutritional support‡ | 10 | 21 | 2 | 4 |
| Dental abnormalities‡ | 10 | 21 | 0 | 0 |
| Sequelae of pre-HCT morbidity‡ | 4 | 8.5 | 2 | 4.5 |
| Late deaths >2 y post-HCT‡ | 5 | 10.5 | 2 | 4.5 |
AIHA, autoimmune hemolytic anemia; IDDM, insulin-dependent diabetes mellitus; ITP, idiopathic thrombocytopenia.
Values are expressed as follows: number of events (number of patients), only the number of events are presented in the subgroups of each type of complications (autoimmunity, infection, miscellaneous).
Noninfectious, nonautoimmune.
Values are expressed as number of patients.